TruScreen Group (TRU) Investor presentation summary

Company overview

• Provides an AI-enabled, real-time cervical cancer screening device with global regulatory approvals.

• Listed on ASX and NZX with a market cap of NZD $13.45m as of May 2026 and 747.3 million shares on issue.

• FY26 annual sales exceeded NZD $2.4m, reflecting 42% year-over-year growth.

• Operates in over 20 countries with more than 1 million women screened and 232 devices operational worldwide.

Technology and clinical validation

• Device uses a single-use sensor and AI algorithm to provide instant, objective results without lab infrastructure.

• Over 1 million women screened with no reported adverse events; device lifespan is 5-7 years.

• Supported by extensive clinical evidence from over 40,000 women in trials and a landmark COGA study with 14,982 participants.

• Demonstrated higher sensitivity and specificity compared to traditional methods like Pap and HPV tests.

Market opportunity and positioning

• Global cervical cancer screening market valued at $7.9bn in 2024, projected to reach $14.5bn by 2033 (5.8% CAGR).

• Significant unmet demand in low- and middle-income countries (LMICs), where screening coverage is well below WHO's 70% target.

• Holds less than 0.1% of the global market and 2.8% of the point-of-care segment, indicating substantial growth potential.

• Core markets include China, India, and Indonesia, accounting for nearly half of global cases.